The Competition Commission of India (CCI) has dismissed a complaint against Cipla and the Bengal Chemist and Druggists Association (BCDA) over alleged non-supply of medicines.
While dismissing the complaint, the fair-trade regulator said the complainant tried to give a commercial dispute between him and Cipla a colour of competition issue. The complainant had alleged that despite placement of repeated orders, Cipla had stopped the supply of medicines at the behest of BCDA.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
